Bellus Health

Investors & Media

Press Releases

Press Releases

5/21/19
BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference
- Clinical results conclusively demonstrate that BLU-5937, a highly selective P2X3 antagonist, is a differentiated product candidate that has little to no impact on taste perception - - Clinical Phase 2 study to assess the efficacy, safety and tolerability of BLU-5937 in chronic cough patients is
2/21/19
BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan
- Reports Financial and Operating Results for the Year Ended December 31, 2018 - LAVAL, QC, Feb. 21, 2019 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need,
Displaying 11 - 17 of 17